The resulting concentration is determined by the ratio of peptide mass to solvent volume
Human clinical trials have not been completed, meaning efficacy and safety in people is not established through rigorous research
Primary CoQ 10 deficiency is characterized by highly heterogeneous clinical signs, with the severity and symptoms varying greatly as is the age of onset, which can be from birth to the seventh decade, and beyond (Salviati et al., 2017)
This will likely improve predictions of binding affinity and provide blueprints for designing next-generation analogues
Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al